WO2003082247A3 - Drug microparticles - Google Patents

Drug microparticles Download PDF

Info

Publication number
WO2003082247A3
WO2003082247A3 PCT/US2003/009327 US0309327W WO03082247A3 WO 2003082247 A3 WO2003082247 A3 WO 2003082247A3 US 0309327 W US0309327 W US 0309327W WO 03082247 A3 WO03082247 A3 WO 03082247A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug microparticles
microparticles
drug
making
methods
Prior art date
Application number
PCT/US2003/009327
Other languages
French (fr)
Other versions
WO2003082247A2 (en
Inventor
Itzhak E Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Original Assignee
Teva Pharma
Itzhak E Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2004-7015217A priority Critical patent/KR20040098023A/en
Priority to CA002480377A priority patent/CA2480377A1/en
Application filed by Teva Pharma, Itzhak E Lerner, Vered Rosenberger, Moshe Flashner-Barak, Anna Drabkin, Naomi Moldavski filed Critical Teva Pharma
Priority to AU2003226021A priority patent/AU2003226021B2/en
Priority to DK03745623.3T priority patent/DK1487416T3/en
Priority to EP03745623A priority patent/EP1487416B1/en
Priority to JP2003579785A priority patent/JP2005531521A/en
Priority to AT03745623T priority patent/ATE450252T1/en
Priority to DE60330322T priority patent/DE60330322D1/en
Priority to IL16415203A priority patent/IL164152A0/en
Priority to MXPA04009385A priority patent/MXPA04009385A/en
Priority to EA200401252A priority patent/EA200401252A1/en
Priority to NZ535854A priority patent/NZ535854A/en
Publication of WO2003082247A2 publication Critical patent/WO2003082247A2/en
Publication of WO2003082247A3 publication Critical patent/WO2003082247A3/en
Priority to HK05102709.3A priority patent/HK1069126A1/en
Priority to AU2008230007A priority patent/AU2008230007A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent

Abstract

Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.
PCT/US2003/009327 2002-03-26 2003-03-25 Drug microparticles WO2003082247A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IL16415203A IL164152A0 (en) 2002-03-26 2003-03-25 Drug microparticles
DE60330322T DE60330322D1 (en) 2002-03-26 2003-03-25 MEDICINES microparticles
AU2003226021A AU2003226021B2 (en) 2002-03-26 2003-03-25 Drug microparticles
CA002480377A CA2480377A1 (en) 2002-03-26 2003-03-25 Drug microparticles
EP03745623A EP1487416B1 (en) 2002-03-26 2003-03-25 Drug microparticles
JP2003579785A JP2005531521A (en) 2002-03-26 2003-03-25 Drag fine particles
MXPA04009385A MXPA04009385A (en) 2002-03-26 2003-03-25 Drug microparticles.
KR10-2004-7015217A KR20040098023A (en) 2002-03-26 2003-03-25 Drug microparticles
DK03745623.3T DK1487416T3 (en) 2002-03-26 2003-03-25 Drug Microparticles
AT03745623T ATE450252T1 (en) 2002-03-26 2003-03-25 MEDICINAL MICROPARTICLES
EA200401252A EA200401252A1 (en) 2002-03-26 2003-03-25 MICROPARTICLES OF MEDICINAL SUBSTANCES
NZ535854A NZ535854A (en) 2002-03-26 2003-03-25 Drug microparticles
HK05102709.3A HK1069126A1 (en) 2002-03-26 2005-03-31 Drug microparticles
AU2008230007A AU2008230007A1 (en) 2002-03-26 2008-10-17 Drug microparticles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36795702P 2002-03-26 2002-03-26
US60/367,957 2002-03-26

Publications (2)

Publication Number Publication Date
WO2003082247A2 WO2003082247A2 (en) 2003-10-09
WO2003082247A3 true WO2003082247A3 (en) 2004-02-05

Family

ID=28675427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009327 WO2003082247A2 (en) 2002-03-26 2003-03-25 Drug microparticles

Country Status (17)

Country Link
US (6) US20030224059A1 (en)
EP (5) EP2087882A1 (en)
JP (1) JP2005531521A (en)
KR (1) KR20040098023A (en)
AT (1) ATE450252T1 (en)
AU (2) AU2003226021B2 (en)
CA (1) CA2480377A1 (en)
DE (1) DE60330322D1 (en)
DK (1) DK1487416T3 (en)
EA (1) EA200401252A1 (en)
ES (1) ES2334991T3 (en)
HK (1) HK1069126A1 (en)
IL (1) IL164152A0 (en)
MX (1) MXPA04009385A (en)
NZ (1) NZ535854A (en)
PT (1) PT1487416E (en)
WO (1) WO2003082247A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224059A1 (en) 2002-03-26 2003-12-04 Lerner E. Itzhak Drug microparticles
AU2003263480A1 (en) * 2002-09-24 2004-04-19 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of fenofibrate having high bioavailability
KR20050116368A (en) * 2003-02-20 2005-12-12 테바 파마슈티컬 인더스트리즈 리미티드 Menthol solutions of drugs
EP1691820A4 (en) 2003-11-08 2010-03-03 Prothera Biolog Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
WO2006020984A2 (en) * 2004-08-13 2006-02-23 Teva Pharmaceutical Industries Ltd. Cyclosporin formulations
JP2008534586A (en) * 2005-03-30 2008-08-28 テバ ファーマシューティカル インダストリーズ リミティド Improved formulation of fenofibrate
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
JP2008505934A (en) * 2005-03-30 2008-02-28 テバ ファーマシューティカル インダストリーズ リミティド Improved formulation of fenofibrate containing menthol or PEG / poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
EP3449928A1 (en) 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US9301919B2 (en) * 2005-12-22 2016-04-05 Oakwood Laboratories, Llc Sublimable sustained release delivery system and method of making same
PT1803441E (en) 2005-12-28 2009-06-08 Teva Pharma Pharmaceutical formulations of fenofibrate having improved bioavailability
BRPI0520821A2 (en) * 2005-12-28 2009-06-30 Teva Pharma fenofibrate pharmaceutical formulations with improved bioavailability
KR20080105174A (en) * 2006-04-03 2008-12-03 테바 파마슈티컬 인더스트리즈 리미티드 Drug microparticles
WO2008110534A1 (en) * 2007-03-13 2008-09-18 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
KR100790954B1 (en) * 2007-09-13 2008-01-04 영남대학교 산학협력단 Novel composite of gelatin ultra-micro capsule containing itraconazole
CN106928346B (en) 2008-05-28 2021-09-07 普罗瑟拉生物公司 Preparation and composition of blood-derived meta-alpha inhibitor proteins
MX2011006307A (en) * 2008-12-15 2011-10-14 Banner Pharmacaps Inc Methods for enhancing the release and absorption of water insoluble active agents.
WO2010085780A1 (en) * 2009-01-26 2010-07-29 Teva Pharmaceutical Industries Ltd. Processes for coating a carrier with microparticles
KR101374854B1 (en) 2009-05-27 2014-03-19 주식회사 삼양바이오팜 Microspheres with improved bioavailability containing poorly water-soluble drugs, and method for preparing same
AU2012275265B2 (en) 2011-06-29 2017-05-04 Covidien Lp Dissolution of oxidized cellulose
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
JP6577865B2 (en) * 2012-04-25 2019-09-18 エスピーアイ ファーマ，インコーポレイテッド Process for producing crystalline microspheres and the same
US9271937B2 (en) 2012-05-31 2016-03-01 Covidien Lp Oxidized cellulose microspheres
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9499636B2 (en) 2012-06-28 2016-11-22 Covidien Lp Dissolution of oxidized cellulose and particle preparation by cross-linking with multivalent cations
CA2885604A1 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of ischemia using inter-alpha inhibitor proteins
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10413566B2 (en) 2013-03-15 2019-09-17 Covidien Lp Thixotropic oxidized cellulose solutions and medical applications thereof
KR20170005819A (en) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
FR3039990B1 (en) 2015-08-10 2018-07-06 Rhodia Operations ENCAPSULATION METHOD
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3463637A4 (en) 2016-05-26 2020-01-29 Allergan, Inc. Production of rounded salt particles
US20180056261A1 (en) * 2016-08-30 2018-03-01 Allergan, Inc. Method of manufacturing coated beads
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2024505429A (en) 2021-01-15 2024-02-06 アクエスティブ セラピューティクス インコーポレイテッド Prodrug compositions and methods of treatment
WO2023015183A1 (en) * 2021-08-02 2023-02-09 Cornell University Polymer nanoparticles via condensed droplet polymerization

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2199973A1 (en) * 1972-09-20 1974-04-19 Boehringer Mannheim Gmbh
WO1991004733A1 (en) * 1989-09-26 1991-04-18 The Mentholatum Company Limited Ibuprofen triturates and topical compositions containing same
WO1993018757A1 (en) * 1992-03-17 1993-09-30 Pfizer Inc. Method of producing porous delivery devices
WO1995008987A1 (en) * 1993-09-28 1995-04-06 Krka Tovarna Zdravil, P.O. Process for preparation of solid disperions and deposits as well as of solid medicinal forms with dihydropyridine type calcium antagonists
WO2001089485A1 (en) * 2000-05-26 2001-11-29 Hanmi Pharm. Co., Ltd. Rapidly disintegrating tablet and process for the manufacture thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
JPS5429566B2 (en) 1974-09-13 1979-09-25
US4900775A (en) * 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
ES2077547T3 (en) * 1992-11-17 2000-06-16 Yoshitomi Pharmaceutical SUSTAINED RELEASE MICROSPHERE CONTAINING AN ANTIPSYCHOTIC AND PRODUCTION PROCEDURE.
IT1264020B (en) * 1993-01-28 1996-09-09 Recordati Chem Pharm PROCEDURE FOR THE PREPARATION OF MICROGRANULES SUITABLE FOR SUSPENSION IN LIQUIDS
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
AU2587297A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
WO1998029098A1 (en) * 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
KR19990001564A (en) 1997-06-16 1999-01-15 유충식 Azole antifungal agents with improved solubility and preparations containing them
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
SE9803240D0 (en) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
DE60140947D1 (en) * 2000-04-26 2010-02-11 Elan Pharma Int Ltd APPARATUS FOR SANITARY WET MASSING
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
CZ2003808A3 (en) 2000-09-20 2003-08-13 Nycomed Pharma As Process for preparing a formulation being present in the form of a liquid emulsion
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20030224059A1 (en) 2002-03-26 2003-12-04 Lerner E. Itzhak Drug microparticles
US20020193386A1 (en) * 2002-03-28 2002-12-19 Inigo Pfeiffer Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004075874A1 (en) 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
US20040185108A1 (en) * 2003-03-18 2004-09-23 Short Robert E. Method of preparing gas-filled polymer matrix microparticles useful for delivering drug
WO2005034908A2 (en) 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
EP1686972B1 (en) 2003-11-21 2008-03-12 Galderma Research & Development Sprayable composition for the administration of vitamin d derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2199973A1 (en) * 1972-09-20 1974-04-19 Boehringer Mannheim Gmbh
WO1991004733A1 (en) * 1989-09-26 1991-04-18 The Mentholatum Company Limited Ibuprofen triturates and topical compositions containing same
WO1993018757A1 (en) * 1992-03-17 1993-09-30 Pfizer Inc. Method of producing porous delivery devices
WO1995008987A1 (en) * 1993-09-28 1995-04-06 Krka Tovarna Zdravil, P.O. Process for preparation of solid disperions and deposits as well as of solid medicinal forms with dihydropyridine type calcium antagonists
WO2001089485A1 (en) * 2000-05-26 2001-11-29 Hanmi Pharm. Co., Ltd. Rapidly disintegrating tablet and process for the manufacture thereof

Also Published As

Publication number Publication date
NZ535854A (en) 2006-08-31
US9107832B2 (en) 2015-08-18
DE60330322D1 (en) 2010-01-14
CA2480377A1 (en) 2003-10-09
EP2087882A1 (en) 2009-08-12
WO2003082247A2 (en) 2003-10-09
EP2085074A1 (en) 2009-08-05
US20140134256A1 (en) 2014-05-15
DK1487416T3 (en) 2010-03-29
US20060141050A1 (en) 2006-06-29
US20030224059A1 (en) 2003-12-04
US20060141051A1 (en) 2006-06-29
JP2005531521A (en) 2005-10-20
ATE450252T1 (en) 2009-12-15
AU2003226021A1 (en) 2003-10-13
MXPA04009385A (en) 2005-01-25
AU2008230007A1 (en) 2008-11-13
KR20040098023A (en) 2004-11-18
EA200401252A1 (en) 2005-04-28
AU2003226021B2 (en) 2008-07-17
US8663703B2 (en) 2014-03-04
HK1069126A1 (en) 2005-05-13
EP1487416B1 (en) 2009-12-02
PT1487416E (en) 2010-01-25
EP1487416A2 (en) 2004-12-22
US20060141052A1 (en) 2006-06-29
IL164152A0 (en) 2005-12-18
ES2334991T3 (en) 2010-03-18
EP2085073A1 (en) 2009-08-05
US20100092568A1 (en) 2010-04-15
EP2085072A1 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
WO2003082247A3 (en) Drug microparticles
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
AU2003258209A1 (en) Active agent delivery systems, medical devices, and methods
AU2003225735A1 (en) Transdermal drug delivery patch system, method of making same and method of using same
WO2004089336A3 (en) Drug delivery systems comprising an encapsulated active ingredient
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004039428A3 (en) Transdermal delivery system for dried particulate or lyophilized medications
WO2003011226A3 (en) Products and drug delivery vehicles
AU2003211376A1 (en) Drug administration method
WO2006035418A3 (en) Microcapsules comprising a methylxanthine and a corticosteroid
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004069138A3 (en) Pharmaceutical formulation
EP1435982A4 (en) Delivery system for pharmaceutical, nutritional and cosmetic ingredients
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2003293593A1 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
AU2003223989A1 (en) System for orally administering active substances, vitamins and/or foodstuffs
MXPA03008420A (en) Solid orally-dispersible pharmaceutical formulation.
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
EP1608395A4 (en) Anticancer agent comprising lk8 protein as an active ingredient
WO2005039481A3 (en) Oral drug delivery system
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
AU2003269792A1 (en) Pharmaceutical formulation of olanzapine
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 164152

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003226021

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003745623

Country of ref document: EP

Ref document number: PA/a/2004/009385

Country of ref document: MX

Ref document number: 1020047015217

Country of ref document: KR

Ref document number: 2480377

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003579785

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 535854

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200401252

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020047015217

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003745623

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003226021

Country of ref document: AU

Date of ref document: 20030325

Kind code of ref document: B